Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

19/12/2016 ​Foundation stone ceremony for Natura Bissé’s new world headquarters in Barcelona Synchrotron Park 15/12/2016 ​The Bioregion of Catalonia in Nature 07/12/2016 Digitus II Awarded By Barcelona Synchrotron Park As Best Business Idea Of The UAB University Research Park 29/11/2016 ​The European Commission awards the “Business & Biodiversity” label to Barcelona Synchrotron Park 21/11/2016 ​Barcelona 2nd Smart City in the World 15/11/2016 Barcelona Synchrotron Park Sponsors the PRUAB Ideas Generation Program
20 21 22 23 24 25 26 27 28 29 30